産前グルココルチコイドの投与タイミングは,早産児の受容体の感受性を決定する
Ingmar Fortmann1,2, Jan Hendric Britsemmer3, Marianne Lehmann4
1Department of pediatrics, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, Lübeck 23562, Germany.
The Journal of clinical endocrinology and metabolism
|February 16, 2026
まとめ
産前グルココルチコイド (aGC) が早産児に投与されると,免疫障害の脆弱性が増加する可能性があります. aGCを母親の昼夜リズムに合わせると,乳児の免疫反応が改善される可能性があります.
科学分野:
- 新生児免疫学について
- シルカディアン生物学
- 薬理学 薬理学とは
背景:
- 早期出産は,世界全体の11%に影響を及ぼします.
- 産前グルココルチコイド (aGC) は胎児の肺の成熟を加速しますが,免疫障害のリスクが増加します.
- aGC投与のタイミングは,乳児の脆弱性に影響を与える可能性があります.
研究 の 目的:
- 母の昼夜リズムに相対してaGC曝露のタイミングが乳児の免疫発達に影響するかどうかを調査する.
- aGCs in-phase (IP) または out-of-phase (OP) に被曝した早産児の免疫マーカーを,母親のコルチゾールピークと比較するために.
主な方法:
- 早産児に関する観察コホート研究.
- 評価されたGC受容体 (GR) の感受性,遺伝子発現 (RNA配列),および外周血液細胞におけるDNAメチル化.
- 比較されたIP,OP,およびコントロール (C) グループ (n=13C,17IP,17OP).
主要な成果:
- オット・オブ・フェーズ (OP) の乳児はGR感受性が低下したことを示した.
- OPの乳児は,抗体生成,白血球の移動,抗原の表示に不可欠な遺伝子の発現を抑制していた.
結論:
- 母の昼夜リズムに合わせたaGCの投与は,乳児の免疫力を強化する可能性があります.
- aGCの曝露を母親のコルチゾールリズムと一致させることで,早産の赤ちゃんが生命の初期に病原菌と戦う能力を向上させることができます.
関連する概念動画
Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
Teratogenicity
4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
Desensitization and Tachyphylaxis
3.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.6K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15


